3.49
price down icon4.64%   -0.17
 
loading
Geron Corp stock is traded at $3.49, with a volume of 24.93M. It is down -4.64% in the last 24 hours and down -12.53% over the past month. Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$3.66
Open:
$3.61
24h Volume:
24.93M
Relative Volume:
2.98
Market Cap:
$2.11B
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-10.26
EPS:
-0.34
Net Cash Flow:
$-216.50M
1W Performance:
-9.59%
1M Performance:
-12.53%
6M Performance:
-21.75%
1Y Performance:
+61.57%
1-Day Range:
Value
$3.455
$3.685
1-Week Range:
Value
$3.455
$4.00
52-Week Range:
Value
$1.64
$5.34

Geron Corp Stock (GERN) Company Profile

Name
Name
Geron Corp
Name
Phone
(650) 473-7700
Name
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Name
Employee
141
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
GERN's Discussions on Twitter

Compare GERN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GERN
Geron Corp
3.49 2.11B 29.48M -201.19M -216.50M -0.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Geron Corp Stock (GERN) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-05-24 Initiated H.C. Wainwright Buy
Oct-16-24 Initiated Scotiabank Sector Outperform
Sep-09-24 Initiated Leerink Partners Outperform
Apr-30-24 Downgrade Robert W. Baird Outperform → Neutral
Apr-29-24 Initiated TD Cowen Buy
Mar-15-24 Reiterated Needham Buy
Sep-12-23 Upgrade Goldman Neutral → Buy
Mar-28-23 Initiated Goldman Neutral
Oct-28-22 Initiated Wedbush Outperform
Jul-28-22 Resumed B. Riley Securities Buy
Nov-02-21 Initiated Robert W. Baird Outperform
Feb-18-21 Resumed B. Riley Securities Buy
Aug-03-20 Initiated Stifel Buy
Nov-19-19 Resumed B. Riley FBR Buy
Sep-03-19 Initiated H.C. Wainwright Buy
Aug-15-19 Initiated Cantor Fitzgerald Overweight
Apr-09-19 Upgrade Needham Hold → Buy
Jan-31-19 Upgrade B. Riley FBR Neutral → Buy
Oct-02-18 Downgrade B. Riley FBR Buy → Neutral
Jul-05-18 Initiated B. Riley FBR, Inc. Buy
Sep-13-16 Reiterated FBR & Co. Outperform
Sep-13-16 Reiterated FBR Capital Outperform
Dec-07-15 Reiterated Piper Jaffray Overweight
Apr-21-15 Initiated Oppenheimer Outperform
Jun-12-14 Upgrade MLV & Co Hold → Buy
Mar-12-14 Downgrade MLV & Co Buy → Hold
Dec-10-13 Reiterated MLV & Co Buy
Dec-10-13 Upgrade Needham Hold → Buy
Nov-08-13 Reiterated MLV & Co Buy
Oct-16-13 Initiated MLV & Co Buy
Aug-30-12 Initiated Stifel Nicolaus Buy
Jun-28-12 Initiated Needham Hold
View All

Geron Corp Stock (GERN) Latest News

pulisher
Dec 20, 2024

Geron (NASDAQ:GERN) Stock Price Down 2.5%Here's Why - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Barclays PLC Has $5.90 Million Stock Holdings in Geron Co. (NASDAQ:GERN) - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Dec 19, 2024
pulisher
Dec 18, 2024

Geron Corporation (NASDAQ:GERN) is a favorite amongst institutional investors who own 72% - Yahoo Finance

Dec 18, 2024
pulisher
Dec 17, 2024

Geron (NASDAQ:GERN) Shares Up 3.7%Here's Why - MarketBeat

Dec 17, 2024
pulisher
Dec 17, 2024

Geron Co. (NASDAQ:GERN) Short Interest Down 5.4% in November - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

Geron's SWOT analysis: biotech stock shows promise amid challenges - Investing.com

Dec 16, 2024
pulisher
Dec 16, 2024

Geron Co. (NASDAQ:GERN) Shares Sold by MML Investors Services LLC - MarketBeat

Dec 16, 2024
pulisher
Dec 15, 2024

State Street Corp Grows Stock Position in Geron Co. (NASDAQ:GERN) - MarketBeat

Dec 15, 2024
pulisher
Dec 14, 2024

Exome Asset Management LLC Invests $4.11 Million in Geron Co. (NASDAQ:GERN) - MarketBeat

Dec 14, 2024
pulisher
Dec 14, 2024

Geron announces positive CHMP opinion for Rytelo - Yahoo Finance

Dec 14, 2024
pulisher
Dec 13, 2024

Geron's (GERN) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat

Dec 13, 2024
pulisher
Dec 13, 2024

World Investment Advisors LLC Increases Stake in Geron Co. (NASDAQ:GERN) - MarketBeat

Dec 13, 2024
pulisher
Dec 13, 2024

Geron's RYTELO nears EU approval for certain blood cancers - Investing.com

Dec 13, 2024
pulisher
Dec 13, 2024

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS - Yahoo Finance

Dec 13, 2024
pulisher
Dec 12, 2024

Geron Co. (NASDAQ:GERN) Shares Bought by Wellington Management Group LLP - MarketBeat

Dec 12, 2024
pulisher
Dec 11, 2024

Stifel sustains Buy on Geron, steady stock target amid ASH updates - Investing.com Canada

Dec 11, 2024
pulisher
Dec 11, 2024

What is Leerink Partnrs' Forecast for Geron FY2026 Earnings? - MarketBeat

Dec 11, 2024
pulisher
Dec 11, 2024

Geron Co. (NASDAQ:GERN) Shares Bought by BNP Paribas Financial Markets - MarketBeat

Dec 11, 2024
pulisher
Dec 11, 2024

Is Geron Corporation (GERN) the Best NASDAQ Penny Stock to Buy Right Now? - Insider Monkey

Dec 11, 2024
pulisher
Dec 10, 2024

Imetelstat shows promise for LR-MDS patients post other therapies - Investing.com

Dec 10, 2024
pulisher
Dec 10, 2024

Geron's RYTELO Shows Strong Safety Profile in Phase 1 Myelofibrosis Trial at ASH Meeting - StockTitan

Dec 10, 2024
pulisher
Dec 10, 2024

HC Wainwright Reaffirms "Buy" Rating for Geron (NASDAQ:GERN) - MarketBeat

Dec 10, 2024
pulisher
Dec 10, 2024

Analyst Scoreboard: 4 Ratings For Geron - Benzinga

Dec 10, 2024
pulisher
Dec 08, 2024

The Manufacturers Life Insurance Company Sells 220,414 Shares of Geron Co. (NASDAQ:GERN) - MarketBeat

Dec 08, 2024
pulisher
Dec 07, 2024

Geron Co. (NASDAQ:GERN) Stock Position Lessened by Fmr LLC - MarketBeat

Dec 07, 2024
pulisher
Dec 05, 2024

Geron Co. (NASDAQ:GERN) Shares Sold by RA Capital Management L.P. - MarketBeat

Dec 05, 2024
pulisher
Dec 05, 2024

RTW Investments LP Makes New $200.27 Million Investment in Geron Co. (NASDAQ:GERN) - MarketBeat

Dec 05, 2024
pulisher
Dec 05, 2024

Janus Henderson Group PLC Acquires 13,163,889 Shares of Geron Co. (NASDAQ:GERN) - MarketBeat

Dec 05, 2024
pulisher
Dec 03, 2024

Geron's SWOT analysis: biopharmaceutical stock poised for growth amid challenges - Investing.com

Dec 03, 2024
pulisher
Dec 02, 2024

Geron Co. (NASDAQ:GERN) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Dec 02, 2024
pulisher
Dec 01, 2024

Walleye Capital LLC Purchases New Shares in Geron Co. (NASDAQ:GERN) - MarketBeat

Dec 01, 2024
pulisher
Nov 30, 2024

Geron (NASDAQ:GERN) Trading Down 3.1%Here's What Happened - MarketBeat

Nov 30, 2024
pulisher
Nov 29, 2024

Vestal Point Capital LP Purchases New Stake in Geron Co. (NASDAQ:GERN) - MarketBeat

Nov 29, 2024
pulisher
Nov 28, 2024

Geron Co. (NASDAQ:GERN) Shares Sold by Ally Bridge Group NY LLC - MarketBeat

Nov 28, 2024
pulisher
Nov 28, 2024

Acuta Capital Partners LLC Acquires New Shares in Geron Co. (NASDAQ:GERN) - MarketBeat

Nov 28, 2024
pulisher
Nov 28, 2024

Intech Investment Management LLC Invests $1.10 Million in Geron Co. (NASDAQ:GERN) - MarketBeat

Nov 28, 2024
pulisher
Nov 28, 2024

Geron Co. (NASDAQ:GERN) Shares Purchased by Algert Global LLC - MarketBeat

Nov 28, 2024
pulisher
Nov 27, 2024

Geron to Present at Evercore ISI HealthCONx Conference This December - StockTitan

Nov 27, 2024
pulisher
Nov 22, 2024

Geron Corp. (GERN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey

Nov 22, 2024
pulisher
Nov 21, 2024

12 NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey

Nov 21, 2024
pulisher
Nov 21, 2024

Geron Grants 1M Stock Options to New Hires at $3.99 Exercise Price | GERN Stock News - StockTitan

Nov 21, 2024
pulisher
Nov 21, 2024

Geron: A Strong Launch And Financial Deals Make It Attractive (NASDAQ:GERN) - Seeking Alpha

Nov 21, 2024
pulisher
Nov 19, 2024

Akin Advises Pharmakon Advisors in its $250 Million Debt Financing for Geron Corporation - Akin Gump Strauss Hauer & Feld LLP

Nov 19, 2024
pulisher
Nov 19, 2024

First Turn Management LLC Takes $14.19 Million Position in Geron Co. (NASDAQ:GERN) - MarketBeat

Nov 19, 2024
pulisher
Nov 15, 2024

RA Capital Management's Strategic Acquisition of Geron Corp Shar - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Deep Track Capital's Strategic Reduction in Geron Corp Holdings - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

RTW INVESTMENTS, LP Acquires New Stake in Geron Corp - GuruFocus.com

Nov 14, 2024
pulisher
Nov 12, 2024

GERNGeron Corp Latest Stock News & Market Updates - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Geron's SWOT analysis: oncology biotech stock poised for growth - Investing.com

Nov 12, 2024
pulisher
Nov 11, 2024

Geron Strengthens Leadership: Top Oncology Expert Dr. Eid Joins as EVP of R&D | GERN Stock News - StockTitan

Nov 11, 2024

Geron Corp Stock (GERN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Geron Corp Stock (GERN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
GRETHLEIN ANDREW J
EVP, Chief Operating Officer
Jul 08 '24
Sale
4.56
674,348
3,073,004
0
Feller Faye
EVP, Chief Medical Officer
Jun 10 '24
Option Exercise
1.19
287,900
341,693
155,400
Feller Faye
EVP, Chief Medical Officer
Jun 10 '24
Sale
4.63
287,900
1,334,129
0
Kapur Anil
EVP, Corp Strategy & CCO
Jun 10 '24
Option Exercise
1.06
421,875
447,188
421,875
Kapur Anil
EVP, Corp Strategy & CCO
Jun 10 '24
Sale
4.64
421,875
1,959,609
0
SCARLETT JOHN A
Chairman, President and CEO
Jun 04 '24
Option Exercise
2.54
600,000
1,524,000
600,000
SCARLETT JOHN A
Chairman, President and CEO
Jun 04 '24
Sale
4.00
600,000
2,400,000
600,000
LAWLIS V BRYAN
Director
May 15 '24
Option Exercise
1.94
35,000
67,900
35,000
LAWLIS V BRYAN
Director
May 15 '24
Sale
3.75
35,000
131,250
0
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Cap:     |  Volume (24h):